Please ensure Javascript is enabled for purposes of website accessibility
Home / Industry / Health Care / Cognivue to join other heavy hitters in Alzheimer’s study (access required)

Cognivue to join other heavy hitters in Alzheimer’s study (access required)

Rochester’s Cognivue Inc. has been selected by the Global Alzheimer’s Platform (GAP) to participate in its pioneering Bio-Hermes clinical trial study. Also participating in the study are Eli Lilly & Co., AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation and other respected biopharma, technology and nonprofit entities. Bio Hermes is the first platform study to investigate and ...
x

Check Also

logo-pandion-optimization

Pandion partners with AI technology firm on health care assistant (access required)

Rochester’s Cognivue Inc. has been selected by the Global Alzheimer’s Platform (GAP) to participate in its pioneering Bio-Hermes clinical trial ...